Argentina issues requirements for diabetes Type 2 clinical research
This article was originally published in SRA
Executive Summary
Argentina’s National Medicines, Food and Medical Technology Administration, ANMAT, has established new requirements – in the form of a guidelines document – for clinical research of Type 2 diabetes treatments, as well as protocol evaluation criteria for such research1,2.
You may also be interested in...
Argentina sets out rules for switching from prescription to OTC status
ANMAT, Argentina's drug and healthcare products regulatory agency, has issued a regulation establishing the minimum requirements that companies need to follow in order to switch their product from prescription-only to over-the-counter status1.
Argentina's ANMAT launches new regulatory strategy
Argentina's National Medicines, Food and Medical Technology Administration, ANMAT, has developed a new strategy to generate timely national and international information about the products and processes within its remit, so that the regulator can identify problems affecting public health and propose appropriate actions1.
Argentina targets tropical diseases, cancer
Argentina's Ministry of Health has recently stepped up its efforts to combat tropical diseases and cancer.